Abstract:OBJECTIVE:To investigate the pathologic and clinical characteristics of patients with liver dysfunction after allogeneic hemopoietic stem cell transplantation (Allo-HSCT), and evaluate the role of liver biopsy in diagnosis and management of liver dysfunction post Allo-HSCT.METHODS:Ten patients with hematological diseases, 5 males and 5 females, aged 34.5 (15-56), underwent Allo-HSCT, 6 receiving Allo-HSCT from their HLA-matched siblings, one receiving haploidentical transplant, two receiving cord blood transplantation from sibling, and one receiving unrelated BMT. The conditioning regimens included Cy/TBI (in 2 cases), and non-TBI regimen (in 8 cases). All the patients received cyclosporine A, short term MTX and MMF for the prophylaxis of graft-versus-host disease (GVHD). Test of liver function and examination of HBV and HCV related serologic markers were performed for the patients and recipients before transplantation and for those who had liver dysfunction after transplantation. Percutaneous liver biopsy was performed for these 10 patients. Biopsy specimens were examined histologically by hematoxylin-eosin staining, Masson staining and immunohistochemical stating of related viruses.RESULTS:All 10 patients showed liver dysfunction on average 3.5 months (2-5 months) after the transplantation. Seven patients positive in HBV and HCV serologic markers before HSCT remained positive after the transplantation. Three patients negative in HBV/HCV markers before and after Allo-HSCT were diagnosed as with GVHD clinically. Eight patients had other manifestations of chronic GVHD. Eight patients received liver biopsy 5.5 months (4-12 months) because of poor improvement in the initial treatment stage. The result of biopsy showed hepatic GVHD in 3 patients and hepatic GVHD concomitant with HBV or HCV hepatitis reactivation in 7 patients. The liver function of 3 patients diagnosed as with hepatic GVHD returned to normal after the use of the second-line anti-GVHD therapy. The other 7 patients used anti-virus agents combined with immunosuppressive agents with the result that 2 patients remained alive with normal liver function and 5 patients died due to pulmonary complication (2 cases) or hepatic failure and hepatic coma (3 cases).CONCLUSION:Liver biopsy is of distinguished diagnostic value for patients with refractory hepatic GVHD after Allo-HSCT. The prognosis is poor for patients having hepatic GVHD concomitant with active hepatic virus infection. At this time the role of liver biopsy is limited and management should be made according to the clinical features and liver pathology.

Liver dysfunction in patients with itraconazole after allogeneic hematopoietic stem cell transplantation:a 53-case etiological analysis

Risk and Prognostic Factors of Transplantation‐associated Thrombotic Microangiopathy in Allogeneic Haematopoietic Stem Cell Transplantation: a Nested Case Control Study

Efficacy and Safety of Itraconazole on Invasive Fungal Infections in 66 Patients with Malignant Hematological Diseases

Relationship Between Gene Polymorphism of Recipient/Donor Immune Pathway and Invasive Fungal Infection after Allogeneic Hematopoietic Stem Cell Transplantation

[Itraconazole for Treatment of Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation].

The Influence of Liver Dysfunction Before Transplantation and During Conditioning Period on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation

Liver Biopsy in the Management of Liver Dysfunction after Allogeneic Hematopoietic Stem-Cell Transplantation

[Characteristics of liver enzyme abnormalities in acute graft-versus-host disease after bone marrow transplantation].

[Graft Versus Host Disease after Liver Transplantation: a Report of 3 Cases].

Etiological diagnosis and management of chronic graft dysfunction after liver transptantation: an analysis of 18 cases

Clinical Study of Liver Injury Associated with Autologous Hematopoietic Stem Cell Transplantation

Clinic risk factors resulting in initial poor graft function after orthotopic liver transplantation:an analysis of 80 cases

PRELIMINARY CHINICAL EXPERIENCE OF LIVER TRANSPLANT-ASSOCIATED GRAFT-VERSUS-HOST DISEASE.

Clinical Features of the Patients with Hepatitis B after Allo-Genetic Hemopoietic Stem Cell Transplantation

Fatal graft-versus-host disease in recipient with pretransplant exposure to immune checkpoint inhibitors and donor-dominant one-way HLA matching after liver transplantation: A case report

[Analysis of Risk Factors for the Development of Acute Graft-Versus-host Disease in 151 Cases of Allo-Hematopoietic Stem Cell Transplantation].

[Exploration of Acute Graft Versus Host Disease and Its Risk Factors after Allo-Hematopoietic Stem Cell Transplantation].

[Unexplained Multiple Effusions As a Manifestation of Chronic Graft-Versus-host Disease after Allogeneic Hematopoietic Transplantation.].

Caspofungin for treatment of invasive fungal infections after allogeneic hematopoietic stem cell transplantation

Clinical Analysis and Proteomic Screening Biomarkers for Graft-Versus-Host Disease After Liver Transplant

Clinical characteristics of acute graft-versus-host disease among different donors of allogeneic hematopoietic stem cell transplantation.